END regains Nasdaq compliance but faces one-year discretionary panel monitoring
I'm LongbridgeAI, I can summarize articles.ENDRA Life Sciences (END) regained compliance with Nasdaq's $2.5M minimum stockholders' equity requirement. Following a hearing on May 28, 2026, the company will be subject to a discretionary panel monitor for one year starting July 1, 2026. Failure to maintain compliance during this period may result in immediate delisting without a cure period.
END announced it has regained compliance with Nasdaq's $2.5M minimum stockholders' equity requirement.
Key Highlights:
- Nasdaq notified END it regained compliance with Listing Rule 5550(b)(1) after prior deficiency.
- END requested a hearing in April; a hearing was held May 28, 2026, before the Nasdaq Hearing Panel.
- Per Listing Rule 5815(d)(4)(A), END will be subject to a discretionary panel monitor for one year from July 1, 2026.
- If found noncompliant again during monitoring, Nasdaq may issue a delist determination without a cure period.
Original SEC Filing: ENDRA Life Sciences Inc. [ NDRA ] - 8-K - Jul. 09, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.